Safety and efficacy of cell-free concentrated ascites reinfusion therapy in gastric cancer patients with refractory ascites

December 2020 | JRMMS

Corresponding Author E-mail:
Published: 24 December 2020


Patients of gastrointestinal carcinoma with the refractory ascites are often chemotherapy-resistant cancer patients, and these patients are good indication of the cell-free and concentrated ascites reinfusion therapy (CART). CART is predicted to enhance symptoms related to refractory ascites of patients with gastrointestinal carcinoma. The aim of this study is to evaluate the safety and efficacy of the CART system performed on the gastric cancer patients with massive refractory ascites. Descriptive cross sectional study. October 2019 to March 2020. Khost Shiekhzayed University Afghanistan. In this retrospective observational study, we evaluated 5 CART processes performed 5 patients with the gastric cancer. We evaluated the effectiveness and adverse events during CART procedures. The amounts of collected and concentrated ascites were 2415.0 ± 1851.7 ml (mean ± SD), and concentration ratio was 11.4 ± 4.5 times. the quantity of collected protein in ascites was 3.5± 1.2 g/dl, and concentration ratio of protein was 5.1 ± 1.8 times. Serum protein level was no significant different between before and fortnight after CART. No patients received an albumin (23% albumin preparation Alb) transfusion within fortnight before the primary CART. Thus, CART allowed for the reduction doses of Alb to be administered. CART has been reported to cause two adverse reactions as elevation of blood heat and reduce in vital sign. In our study, decreased vital sign wasn't observed altogether patients, and blood heat significantly rose after CART, but there have been no patients quite 38 degrees. In patients with refractory ascites of the gastric cancer patients in whom complete cure can't be expected, CART improves their QOL and, in terms of medical economy, allows for the reduction doses of Alb. CART are often effectively applied as a palliative procedure for refractory ascites of the gastric cancer patients.


Cell-free concentrated ascites reinfusion therapy, Gastric cancer, Palliative procedure, Refractory ascites

Read: [Full Text - PDF]